Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
June 1, 2017
This recent publication describes the work James McCarthy led to first test the safety of a New Chemical Entity in humans then to define its antimalarial activity in the human challenge system he developed.